Chronic antibody mediated 
rejection (Banff cg >0) p-value Allograft survival p-value
Group No 
eculizumab +eculizumab No 
eculizumab +eculizumab
+DSA/low+XM 10/34
(29.4%)
1/2
(50.0%) P=0.52 33/34
(97.1%)
2/2
(100.0%)
P=1.0
+DSA/high+XM 3/8
(37.5%)
19/35 
(54.3%) P=0.46 6/8
(75.0%)
28/35
(80.0%)
P=0.14
No 
bortezomib +bortezomib No 
bortezomib +bortezomib
+DSA/low+XM 11/36
(30.6%) NA 35/36
(97.2%) NA
+DSA/high+XM 18/36 
(50.0%)
4/7
(57.1%) P=1.0 29/36
(80.1%)
5/7
(71.4%) P=0.62
Table S1: Chronic antibody mediated rejection and death censored allograft 
survival stratified by group and desensitization therapy.

